Accretion Pharmaceuticals (NSE:ACCPL) EBIT: ₹139.3 Mil (TTM As of Mar. 2026)


NSE:ACCPL Accretion Pharmaceuticals Ltd NSE:ACCPL
18 GF Score
Price ₹149.15
! 5 Warning Signs
View Full Analysis

What is Accretion Pharmaceuticals EBIT?

Accretion Pharmaceuticals NSE:ACCPL -1.81% 18 EBIT is ₹139.3 Mil as of Mar. 2026. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Accretion Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹71.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹139.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Accretion Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was 16.92%. Accretion Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 26.74%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Accretion Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.00%.

Accretion Pharmaceuticals  (NSE:ACCPL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Accretion Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=141.39 * ( 1 - 26.33% )/( (562.451 + 668.692)/ 2 )
=104.162013/615.5715
=16.92 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=590.747 - 26.738 - ( 1.558 - max(0, 115.118 - 500.468+1.558))
=562.451

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=766.555 - 57.657 - ( 40.206 - max(0, 208.121 - 605.931+40.206))
=668.692

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Accretion Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=142.99/( ( (86.666 + max(431.762, 0)) + (134.137 + max(416.784, 0)) )/ 2 )
=142.99/( ( 518.428 + 550.921 )/ 2 )
=142.99/534.6745
=26.74 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(218.482 + 228.346 + 28.943) - (26.738 + 0 + 17.271)
=431.762

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(224.001 + 283.746 + 2.571) - (57.657 + 0 + 35.877)
=416.784

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Accretion Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=139.309/1740.957
=8.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Pharmaceuticals EBIT Related Terms

Accretion Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Accretion Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Pharmaceuticals EBIT Chart

Accretion Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
11.02 11.64 68.23 112.01 139.31

Accretion Pharmaceuticals Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial 0.00 39.88 72.13 67.81 71.50

NSE:ACCPL vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accretion Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Accretion Pharmaceuticals's EV-to-EBIT falls into.


NSE:ACCPL
18GF Score
Accretion Pharmaceuticals Ltd NSE:ACCPL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accretion Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹139.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹139.3 Mil mean?
Accretion Pharmaceuticals (NSE:ACCPL) has a EBIT of ₹139.3 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Accretion Pharmaceuticals.
Is Accretion Pharmaceuticals' EBIT too high?
Accretion Pharmaceuticals' current EBIT is ₹139.3 Mil. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' EBIT compare to LLY and JNJ?
Accretion Pharmaceuticals' EBIT of ₹139.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Accretion Pharmaceuticals. Accretion Pharmaceuticals's current EBIT is ₹139.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current EBIT of ₹139.3 Mil. The current EBIT is ₹139.3 Mil. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current EBIT is ₹139.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accretion Pharmaceuticals Business Description

Address 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna-Chacharwadi, Ta - Sanand District, Ahmedabad, GJ, IND, 382213
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score

Get the complete analysis for NSE:ACCPL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹149.15
Price